論文・技術情報追加のお知らせ

1. Oral adverse events associated with antiseizure medications: An analysis of the FDA adverse event reporting system (FAERS) database.

抗てんかん薬の口腔副作用が16薬で確認

対象DB：FAERS

2. Selective Serotonin Reuptake Inhibitor-Associated Intracranial Hemorrhage: Drug-Specific Risk Patterns and Patient-Level Modifiers.

SSRI関連ICHリスク、特定薬・高齢者・抗凝固薬で増加

対象DB：FAERS

3. Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013-2023.

タクロリムス等3剤の安全性評価、心理影響含め慎重監視必須

対象DB：FAERS

4. Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System.

薬剤性白内障、長期薬剤使用で視覚リスク高

対象DB：FAERS

5. beta-blockers and risk of neuropsychiatric adverse events: An active-comparator restricted disproportionality on the FAERS.

β遮断薬、特にプロプラノロールは精神神経リスク高

対象DB：FAERS

6. Paradoxical psoriasis in pediatric tumor necrosis factor-alpha inhibitor therapy database.

TNFi小児PPは0.58%、4薬で報告。監視必要

対象DB：FAERS

7. Analysis and mining of L-ornithine L-aspartate adverse events based on FAERS database.

LOLAは肝胆障害リスクが高く、長期安全性研究と慎重なモニタリングが重要

対象DB：FAERS

8. Current and emerging data sources for assessment of ovarian toxicity in children, adolescents and young adults with cancer.

若年がん患者の生殖健康維持へ、毒性データ改善と新評価法が急務

対象DB：FAERS

9. Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database.

GLP-1 RA誘発胆嚢炎・胆石は182日で発現、特に45歳以上女性が高リスク

対象DB：FAERS

10. Principal component analysis of antiseizure medication-induced hostility/aggression and factor analysis of levetiracetam using the food and drug administration adverse event reporting system.

レベチラセタム誘発敵意は早期発現が重要

対象DB：FAERS

11. Isavuconazole and Calcium Channel Blocker for Invasive Fungal Disease Accompanied With Hypertension: Evidence From the FAERS and PBPK/PD Model.

ISAは、高血圧を伴うIFD患者のCCBs併用時に安全で、DDIリスクは最小

対象DB：FAERS

12. Skin toxicity associated with immune checkpoint inhibitors based on the FDA adverse event reporting system 2011 - 2023 data.

ICIsで皮膚毒性発現、PD-1死亡率最高、早期監視が必要

対象DB：FAERS

13. Efficacy and safety of bisphosphonates in pediatric glucocorticoid-induced osteoporosis: a meta-analysis and pharmacovigilance study.

小児のGC誘発性骨粗鬆症にビスホスホネート有効ながら副作用注意必要

対象DB：FAERS

14. Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database.

プロテアソーム阻害剤の初月ADE多発

対象DB：FAERS

15. Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS.

アニフロルマブ使用で初月に多様な副作用判明

対象DB：FAERS

16. An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.

アデフォビルとテノフォビルは骨粗鬆症リスクに影響

対象DB：FAERS

17. National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023).

口腔AEの解析が重要、味覚障害など透明性向上が必要

対象DB：FAERS,VAERS

18. Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS).

NIVO-IPIは免疫関連毒性が広範、NIVO-RELAは心障害リスク増

対象DB：FAERS

19. Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System (FEARS).

SOSに関連する薬剤としてオキサリプラチンとブスルファンが注目

対象DB：FAERS

20. Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database.

FGFR-TKIsの新規有害事象が実臨床で報告

対象DB：FAERS

21. Trends in the use of sodium-glucose cotransporter-2 inhibitors and characteristics of adverse event reporting in patients with heart failure in Japan: reports from the medical administration database and the adverse event reporting database.

SGLT2阻害薬は心不全に有効だが高齢患者で脱水や腎障害に注意が必要

対象DB：JADER,JMDC

22. Nephrotoxicity of New Antibiotics: A Systematic Review.

新規抗生物質の腎毒性リスクは低頻度だが、さらなる調査と報告が必要

対象DB：EudraVigilance,VigiBase

23. Drugs used in diabetes, statins and the risk of rhabdomyolysis reporting: a disproportionality analysis in the world health organization's pharmacovigilance database.

糖尿病治療薬とスタチン併用で横紋筋融解症リスク増加

対象DB：VigiBase

24. Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase.

CAR-T療法の副作用は高頻度かつ重篤

対象DB：VigiBase

25. Drug-induced fluorosis: A study based on the national and international pharmacovigilance databases.

フッ素化合物は、薬剤誘発性フルオロシスのリスクに関連

対象DB：VigiBase

26. Impact of osteoporosis on perioperative complications in patients undergoing surgical treatment for lumbar spinal stenosis: a nationwide retrospective study.

骨粗鬆症はLSS手術の術後合併症リスク因子

対象DB：DPC

27. Risk Factors for Airway Complications After Thyroplasty and Arytenoid Adduction.

気道合併症リスクに高齢、術式の複雑性、抗血小板薬などが関与

対象DB：DPC

28. Risk factors for nephropathy in individuals with new-onset type 2 diabetes undergoing treatment for hypertension: A retrospective analysis using the Diagnosis Procedure Combination database.

糖尿病腎症のリスク要因は年齢、eGFR、脂質異常

対象DB：DPC

29. Impact of ongoing glucocorticoid use on postoperative complications following Total knee arthroplasty: a Japanese Nationwide propensity score-matched cohort study.

TKA後のグルココルチコイド使用は肺炎リスク増

対象DB：DPC

30. Changes in the Use of Telephone Follow-ups among Patients with Urologic Malignancies in Japan.

COVID-19の影響で泌尿器がん患者の電話フォローアップが増加

対象DB：JMDC

31. The Proportion of Coinfections Among Sexually Transmitted Infections in Japan: A Nationwide Claims Database Study.

若年層でSTIの重複感染率が高く、早期診断と予防対策が重要

対象DB：NDB

32. Positive Impact of Health Check-Ups and Guidance in the General Population: A Database-Based Cohort Study in Japan.

特定健診は健康改善と疾患予防に有効。定期受診が重要

対象DB：NDB

33. Lifetime risk, sex and age differences in annual incidence of ocular motor cranial nerve palsy in Japan for 2019.

日本でOMCNPは加齢とともに増加、男性で多い

対象DB：NDB

34. Incidence and Healthcare Resource Utilization Among Patients with Hypertrophic Cardiomyopathy Hospitalized for Heart Failure in Japan.

HCM患者のHF入院は高い臨床および経済的負担を伴う

対象DB：MDV

35. Major Adverse Cardiovascular Events and Cause-Specific Mortality After Hospitalisation in COPD.

COPD入院後の1年でMACE・死亡率増加

対象DB：CPRD

36. Clustering of electronic health records in atrial fibrillation patients and impact on prognosis and patient trajectories: a UK linked-dataset study.

AIでAF患者を5群に分類し、異なる特徴と予後を提案

対象DB：CPRD

37. Risk of Severe Exacerbation Associated with Gabapentinoid Use in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.

COPD患者のガバペンチノイド使用は増悪リスク増加

対象DB：CPRD

38. Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in England.

T2DMは肺癌後の心血管・呼吸疾患死亡率を増加させる

対象DB：CPRD

39. Can the epidemiology of zoonotic disease be studied in routine health records? A feasibility study of the Clinical Practice Research Datalink (CPRD).

CPRDは人獣共通感染症監視の補完手段、有効性確認

対象DB：CPRD

40. Body mass index and infection risks in people with and without type 2 diabetes: A cohort study using electronic health records.

BMIと感染リスクは両群ともU字型関係が確認

対象DB：CPRD

41. Development of an algorithm for ethnicity recording in cohorts from the UK Clinical Practice Research Datalink primary care and linked Hospital Episode Statistics databases.

CPRD民族性アルゴリズム評価で高一致度、多データ利用が有効

対象DB：CPRD